ReviewBritish journal of cancer2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Review in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Myocardial infarction with non-obstructive coronary arteries and newly diagnosed cancer: is there a link? Case report.European heart journal. Case reports · 2026Article
- Unravelling theTheranostics · 2026Article
- The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib.Journal of clinical medicine · 2026Review
- Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib.Frontiers in immunology · 2026Article
- Rare Metastatic Pathways of Renal Cell Carcinoma: Duodenal Involvement and Therapeutic Challenges.Clinical case reports · 2025Article
- Using Electronic Patient-Reported Outcome Measures for Patients With Metastatic Renal Cell Carcinoma: A Narrative Review.Clinical journal of oncology nursing · 2025Review
- Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data.Clinical Medicine Insights. Oncology · 2025Article
- Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist.Therapeutic advances in gastroenterology · 2025Review
- Article
- Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.Blood advances · 2024Article
- Beyond the Checkpoint: Severe Axitinib-induced Liver Injury.ACG case reports journal · 2023Article
- Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.Advances in therapy · 2023Article
- Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes.International journal of clinical oncology · 2023Article
- Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?Cancers · 2023Review
- The need for kidney biopsy in the management of side effects of target and immunotherapy.Frontiers in nephrology · 2023Article
- Supportive therapy and complementary medicine in renal cell carcinoma.World journal of urology · 2022Article
- Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice.Current oncology (Toronto, Ont.) · 2022Article
- Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.Drugs · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
Abstract
With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib-ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib-ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib-ICI combinations with the aim to improve the safety of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.